Quest Diagnostics is headquartered in Madison, US

Report incorrect company information

Chairman, President and Chief Executive Officer

Report incorrect company information

Quest Diagnostics has an office in Madison

Madison, US (HQ)

Giralda Farms

Report incorrect company information

Quest Diagnostics's revenue was reported to be $7.52 b in FY, 2016 which is a **0.3% increase** from the previous period.

USD | |
---|---|

## Revenue (Q3, 2017) | 1.9 b |

## Gross profit (Q3, 2017) | 741 m |

## Gross profit margin (Q3, 2017), % | 38.4% |

## Net income (Q3, 2017) | 175 m |

## EBIT (Q3, 2017) | 298 m |

## Market capitalization (3-Mar-2018) | 14.2 b |

## Cash (4-Mar-2018) | 350 m |

## EV | 17.6 b |

Quest Diagnostics's current market capitalization is $14.2 b.

- Source: SEC Filings

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 7.1 b | 7.4 b | 7.5 b | 7.5 b |

| 4% | 1% | 0% | |

## Cost of goods sold | 4.3 b | 4.6 b | 4.7 b | 4.6 b |

## Gross profit | 2.8 b | 2.8 b | 2.8 b | 2.9 b |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.8 b | 1.7 b | 1.9 b | 1.9 b | 1.8 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b |

## Cost of goods sold | 1.1 b | 1.1 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.1 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b |

## Gross profit | 698.6 m | 645 m | 728 m | 726 m | 676 m | 743 m | 718 m | 719 m | 751 m | 728 m | 734 m | 773 m | 741 m |

| 39% | 37% | 38% | 38% | 37% | 39% | 38% | 39% | 39% | 39% | 39% | 40% | 38% |

- Source: SEC Filings

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 187 m | 192 m | 133 m | 359 m |

## Inventories | 91 m | 110 m | 84 m | 82 m |

## Current Assets | 1.4 b | 1.6 b | 1.5 b | 1.5 b |

## PP&E | 805 m | 933 m | 925 m | 1 b |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 158.3 m | 144 m | 144 m | 170 m | 974 m | 150 m | 123 m | 128 m | 283 m | 406 m | 367 m | 314 m | 350 m |

## Inventories | 85.2 m | 99 m | 109 m | 111 m | 106 m | 109 m | 86 m | 82 m | 80 m | 82 m | 77 m | 83 m | 100 m |

## Current Assets | 1.4 b | 1.5 b | 1.5 b | 1.6 b | 2.4 b | 1.5 b | 1.6 b | 1.5 b | 1.5 b | 1.6 b | 1.6 b | 1.5 b | 1.5 b |

## PP&E | 749.4 m | 851 m | 884 m | 888 m | 902 m | 906 m | 886 m | 925 m | 937 m | 952 m | 1 b | 1 b | 1.1 b |

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | 883 m | 592 m | 753 m | 696 m |

## Accounts Payable | (21 m) | 68 m | (31 m) | 56 m |

## Cash From Operating Activities | 652 m | 938 m | 810 m | 1.1 b |

## Cash From Investing Activities | 328 m | (1 b) | (362 m) | (152 m) |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 732.1 m | 111 m | 253 m | 392 m | 70 m | 199 m | 553 m | 114 m | 324 m | 529 m | 175 m | 382 m | 557 m |

## Depreciation and Amortization | 211 m | 75 m | 156 m | 235 m | 78 m | 153 m | 230 m | 62 m | 123 m | 186 m | 62 m | 128 m | 197 m |

## Accounts Payable | (76.8 m) | (86 m) | (39 m) | 20 m | (120 m) | (49 m) | (41 m) | (77 m) | 23 m | 43 m | (95 m) | (93 m) | (3 m) |

## Cash From Operating Activities | 441.6 m | 84 m | 364 m | 635 m | 52 m | 327 m | 539 m | 143 m | 464 m | 765 m | 196 m | 490 m | 852 m |

USD | Y, 2017 |
---|---|

## EV/EBIT | 59.2 x |

## EV/CFO | 20.7 x |

## EV/FCF | 25.9 x |

## Revenue/Employee | 44.9 k |

## Financial Leverage | 2.2 x |

FY, 2016 | |
---|---|

## Accounts | 250 k |

## Patents Issued | 700 |

## Patents Pending | 570 |

## Patient Service Centers | 2.20 k |

Acquired Company | Date | Deal Size |
---|---|---|

California Laboratory Associates | October 30, 2017 | |

Cleveland HeartLab | October 18, 2017 | |

Cape Cod Healthcare - Business | June 28, 2017 | |

ClearPoint Diagnostic | June 12, 2017 | |

Med fusion | June 12, 2017 | |

PeaceHealth Laboratories | February 15, 2017 |

Report incorrect company information

January 09, 2018

Cellular Health Screening/Health Testing -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

January 04, 2018

HTF MI published a new industry research that focuses on Esoteric Testing market and delivers in-depth market analysis and future prospects of Global Esoteric Testing market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Report incorrect company information